Establishment Labs Hldgs Inc Stock Price, News & Analysis

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a company specializing in women's health, will feature CEO Juan José Chacón-Quirós and CFO Renee Gaeta at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. Their presentation is scheduled for June 4 at 2:00 pm ET. A live webcast will be accessible on the Establishment Labs investor relations website, with an archived version available later. The company designs and manufactures silicone gel-filled breast implants under the Motiva Implants® brand, complying with FDA and ISO standards, and has a presence in over 80 countries.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has appointed Pratip Dastidar as the Head of Global Operations, aiming to enhance operational transformation and global scaling. With a robust background from ServiceMaster and Salesforce, Dastidar's experience is expected to drive digital initiatives. CEO Juan José Chacón-Quirós emphasized the alignment of operations with growth strategies. Salvador Dada will return as Head of Special Projects, overseeing new manufacturing and R&D facilities in Costa Rica to support expansion into markets like China and the U.S.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced participation in the UBS Global Healthcare Virtual Conference, taking place from May 24-26, 2021. CEO Juan José Chacón-Quirós and CFO Renee Gaeta will present on May 24, 2021, at 9:00 am ET. A live webcast will be available on the company's investor relations website, with an archived version accessible afterward. Establishment Labs specializes in women’s health, focusing on breast aesthetics and reconstruction, and markets silicone gel-filled Motiva Implants®, available in over 80 countries.

Establishment Labs Holdings (NASDAQ: ESTA) reported a record $30.3 million in sales for Q1 2021, up 24% from the previous year. The company raised its full-year revenue guidance to $118-$122 million, reflecting a 39% to 44% growth. First-quarter gross profit increased to $20.1 million (66.2% of revenue), while operating expenses decreased to $22.2 million. The net loss from operations improved to $2.1 million compared to $7.7 million in Q1 2020. The cash balance as of March 31, 2021, stood at $78 million, despite a $6.6 million decrease from the prior quarter.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced the completion of enrollment in its 100-patient Motiva Mia^® case series in Costa Rica, approved by the Institutional Review Board. The study began in December 2020, following a previous case series in Asia. Led by 15 board-certified plastic surgeons from various countries, this prospective study aims to assess a minimally invasive breast enhancement procedure. The company has also submitted tools for CE marking, marking significant progress in its global regulatory strategy.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is set to announce its financial results for Q1 2021 on May 5, 2021, before market opens. A conference call will follow at 8:30 am ET. Establishment Labs specializes in women's health, particularly in breast aesthetics and reconstruction, offering innovative silicone gel-filled breast implants branded as Motiva Implants®. These implants are available in over 80 countries and produced in compliance with strict quality standards.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported record fourth quarter sales of $27.0 million, up 11% year-over-year, and provided 2021 guidance of $110 million to $112 million, reflecting a 30% to 32% growth. Operating expenses rose to $22.7 million, with a net loss from operations of $8.0 million. The company maintains a robust cash balance of $84.5 million. Key advancements include receiving CE mark for the new Motiva Ergonomix2 silicone implants and progress toward U.S. and Chinese market entry, with a total addressable market for Motiva Mia estimated at $4-5 billion.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has appointed Raj Denhoy as Head of Strategy and Investor Relations. Denhoy, formerly with Jefferies Group, brings over two decades of experience in the medical device industry. His role will involve defining corporate strategy and enhancing investor communication as the company aims for global leadership in breast aesthetics and reconstruction. Denhoy emphasized potential growth through the global rollout of Motiva implants and the upcoming MIA procedure, signaling optimism for sustained value creation.

Establishment Labs Holdings (NASDAQ: ESTA) is set to announce its financial results for Q4 2020 on March 10, 2021, before market open. A conference call will follow at 8:30 AM ET to discuss these results. The company specializes in women’s health, primarily in breast aesthetics, with its innovative Motiva Implants® and related technologies. Products are available in over 80 countries, adhering to strict regulatory standards. The company also initiated a clinical trial in the U.S. for Motiva Implants® after receiving FDA approval in March 2018.